Coherus Medical, a biotech developing knockoffs of some of the world’s top-selling treatments, is plotting an $86 million IPO to bankroll its late-stage R&D work. …read more Source: Biosimilars outfit Coherus pitches an $86M IPO, targeting Enbrel and Humira     

…read more Source: GSK taps Royal Bank of Scotland chair Philip Hampton to lead its own board     

Takeda Pharmaceutical has stepped up with a $25 million investment in Cleveland’s BioMotiv, buying into the accelerator’s promise to transform academic discoveries into market-bound therapeutics. …read more Source: Takeda pours $25M into biotech dealmaker BioMotiv     

Gilead Sciences, already a trailblazer in hepatitis C treatment, is creeping up on its next milestone: approval for a combination therapy that promises to cure the majority of patients without the need for painful injections. …read more Source: Gilead nears EU approval for the next big thing in hep C     

Novo Nordisk has made it official: The Danish drugmaker is making a full-fledged go at obesity R&D, looking to build a Seattle hub and hire up some investigators as it expands its research palate. …read more Source: Novo dishes on its new Seattle R&D shop and seeks out new ideas in obesity     

German drug developer Probiodrug is looking to go public on the Amsterdam exchange, seeking funds to advance its pipeline of treatments for Alzheimer’s disease as more and more European biotechs set sights on IPOs. …read more Source: Alzheimer’s biotech Probiodrug plots a Euro IPO amid a continental boomlet     

Welcome to the latest edition of our weekly EuroBiotech Report. …read more Source: EU IPOs: Up on ’13, down on U.S., CRUK, MedImmune to run lab, Clal sues Hyperion     

Valeant Pharmaceuticals is famous for its aversion to pharmaceutical R&D, but the serial acquirer makes an exception when it sees blockbuster promise in a late-stage asset. And that’s the case for the glaucoma treatment Vesneo, which met its goals in pivotal trials and, according to the company, has blockbuster potential. …read more Source: Valeant talks […]

Jockeying with a slew of next-generation treatments, Novartis’ new anti-inflammatory drug succeeded in two Phase III trials on patients with psoriatic arthritis, stoking the company’s hopes of snagging significant market share once it wins approval. …read more Source: Novartis’ blockbuster hopeful scores a win in psoriatic arthritis     

…read more Source: Regado slashes staff to preserve cash following PhIII fiasco